Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure
A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults With Thrombocytopenia Associated With Liver Disease Prior to an Elective Procedure
Sponsor: Eisai Inc.
A PHASE3 clinical study on Thrombocytopenia Associated With Liver Disease, this trial is completed. The trial is conducted by Eisai Inc. and has accumulated 9 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
Mar 2018 — Jun 2018 [monthly]
Completed PHASE3
-
Jul 2017 — Mar 2018 [monthly]
Completed PHASE3
Status: Recruiting → Completed
-
Feb 2017 — Jul 2017 [monthly]
Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Nov 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eisai Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aracaju, Brazil , Arad, Romania , Baggiovara, Italy , Baltimore, United States , Barcelona, Spain , Beijing, China , Birmingham, United States , Bonn, Germany , Boston, United States , Botucatu, Brazil and 108 more locations